文献速递类风湿关节炎其他结缔组织病

特发性肺纤维化来源的多生物标志物组合在类风湿关节炎相关间质性肺病中的表现

Performance of an Idiopathic Pulmonary Fibrosis-Derived Multibiomarker Panel for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
PubMed 文献 · Arthritis Rheumatol · 2026-01-11

研究评估与特发性肺纤维化(IPF)相关的8种外周血生物标志物组合在类风湿关节炎(RA)患者中与间质性肺病(ILD)的关联。在两个RA开发队列(n=93和n=71)中,RA-ILD患者的多生物标志物评分显著高于单纯RA患者;在独立多中心前瞻性美国退伍军人RA队列(n=2,507)中,最高四分位评分者患病ILD的校正OR为2.14(95%CI 1.18-3.87),发生ILD的校正HR为2.45(95%CI 1.55-3.88)。结论认为该IPF来源的生物标志物组合与RA-ILD相关,支持两者共享病因学概念,并展示外周血生物标志物组合对RA患者ILD风险分层的潜力。

要点

  • 两个RA开发队列中,RA-ILD患者IPF多生物标志物评分显著高于单纯RA患者。
  • 验证队列中最高四分位评分者患病ILD的校正OR为2.14(95%CI 1.18-3.87)。
  • 最高四分位评分者发生ILD的校正HR为2.45(95%CI 1.55-3.88),15年累积风险近20%。

核心结论

  • 源自IPF相关生物标志物的多生物标志物组合在独立开发与验证队列中均与RA-ILD相关。
  • 这种重叠支持IPF与RA-ILD共享病因学的概念,并展示外周血生物标志物组合对RA患者ILD风险分层的潜力。

研究设计与样本

  • 研究首先在两个独立的RA队列(n=93和n=71)中评估IPF相关生物标志物组合与患病ILD的关联。
  • 随后在一个独立的美国退伍军人RA多中心前瞻性队列(n=2,507)中验证该评分(去除MMP-2)与患病及发生ILD的关联,多变量回归模型校正了相关协变量。

主要发现

  • 在两个开发队列中,RA-ILD患者的IPF多生物标志物评分显著高于单纯RA患者。
  • 在独立验证队列中,多生物标志物评分最高四分位者患病ILD的校正OR为2.14(95%CI 1.18-3.87),发生ILD的校正HR为2.45(95%CI 1.55-3.88),均以最低四分位为参照。
  • 最高四分位者15年发生ILD的累积风险接近20%,而其他所有四分位合计低于10%。

关键数值与推荐

  • 采用8种IPF相关生物标志物(嗜酸性粒细胞趋化因子、Flt-3L、白细胞介素-8、巨噬细胞来源趋化因子、单核细胞趋化蛋白1及基质金属蛋白酶2/7/9)标准化后求和生成多生物标志物评分。
  • 验证队列中使用的评分去除了MMP-2。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. METHODS: We first assessed the association of a panel of IPF-associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF-related biomarkers (eotaxin, Flt-3L, interleukin-8, macrophage-derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP-2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP-2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. RESULTS: In both development cohorts, participants with RA-ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18-3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55-3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. CONCLUSION: A multibiomarker panel derived from IPF-associated biomarkers was associated with RA-ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA-ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Luedders BA, Kass D, Baker JF, et al. Performance of an Idiopathic Pulmonary Fibrosis-Derived Multibiomarker Panel for Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2026. PMID: 40955640. doi:10.1002/art.43383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。